Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report.
Gorkem TurkkanCaner DoganBurak TekPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2019)
The pathophysiology of bicalutamide-induced hallucinations is unclear. We hypothesize that antiandrogens can indirectly cause hallucinations through changes in plasma testosterone and cerebral reelin expression. Additionally, luteinizing hormone-releasing hormone agonist monotherapy is a good option in metastatic prostate cancer patients who have intolerable side effects due to the use of antiandrogens.
Keyphrases
- prostate cancer
- squamous cell carcinoma
- small cell lung cancer
- radical prostatectomy
- poor prognosis
- high glucose
- case report
- diabetic rats
- subarachnoid hemorrhage
- combination therapy
- drug induced
- replacement therapy
- open label
- binding protein
- randomized controlled trial
- clinical trial
- oxidative stress
- long non coding rna
- blood brain barrier
- brain injury